Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Time Will Tell Whether Once-monthly Products Ultimately Dominate or Merely Provide Another Option in the BP Market
November 12, 2012
- Sales Increase 3.4% as Generics Make Large Gains: Kyorin HD
November 9, 2012
- Novartis Files for Approval for LABA, LAMA Combination Treatment for COPD in Japan
November 9, 2012
- 1st-Half Settlements of Top 4 Wholesalers Suggest Recovery in Operating Profit Rates in Core Drug Business
November 9, 2012
- US FDA Approves Pfizer’s Novel RA Treatment Tofacitinib
November 9, 2012
- Four Companies Discontinue Marketing Atelec Generics Due to Halt in Supplies of Bulk Drug Substance
November 9, 2012
- Sales Down by 7.8% due to Slump of Long-Listed Drugs, Transfer of Marketing Rights for Cabaser: Kissei
November 8, 2012
- Nippon Shinyaku Confident about Achieving Target in Mid-Term Management Plan Backed by Steady Growth of New Products
November 8, 2012
- Ono: New Products Grow in 1st Half, Glactiv to Become Top-Selling Product
November 8, 2012
- Alfresa HD “Reached Some Degree of Agreement with Customers” Despite Non-Agreement Rate of Over 60% in 1st Half: President Ishiguro
November 8, 2012
- Kyorin Drops Development of DPP-4 Inhibitor as It Fails to Find Partner
November 8, 2012
- Otsuka Forms JV with Turkey’s No. 1 Drug Maker, Set to Launch Samsca in 2013
November 7, 2012
- Tolvaptan Suppresses Rate of Increase in Total Kidney Volume by 50%: Otsuka
November 7, 2012
- Eli Lilly Japan, Chugai to Terminate Comarketing Agreement for Evista
November 7, 2012
- Takeda to Buy Envoy of US to Reinforce Drug Discovery Prowess
November 7, 2012
- Ono Achieves Target Reduction of Sales Ratio of Long-Listed Drugs to Mid-50% Level: President Sagara
November 7, 2012
- Generic Sales Ratio Exceeds 80% for First Time in Interim Results: Nippon Chemiphar
November 6, 2012
- Abbott Splits into Two Companies; Research-Based Pharmaceuticals, Diversified Medical Products
November 6, 2012
- Abbott Japan Spins Off New Drug Biz, Establishes New Firm “AbbVie”
November 6, 2012
- Sawai’s Status Improved Within Mediceo by Utilizing ARs
November 6, 2012
ページ
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s leading pharmaceutical wholesalers are bracing for a second consecutive year of profit declines, underscoring the growing challenge of generating…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…